Globus Medical (NYSE: GMED) is one of 80 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its competitors? We will compare Globus Medical to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.
This is a breakdown of recent recommendations for Globus Medical and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Globus Medical Competitors||205||1198||2673||86||2.63|
Globus Medical currently has a consensus target price of $34.00, indicating a potential downside of 10.05%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.41%. Given Globus Medical’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Globus Medical has less favorable growth aspects than its competitors.
Insider and Institutional Ownership
65.6% of Globus Medical shares are owned by institutional investors. Comparatively, 67.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 28.2% of Globus Medical shares are owned by insiders. Comparatively, 11.7% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Globus Medical and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Globus Medical||$563.99 million||$104.34 million||34.36|
|Globus Medical Competitors||$1.03 billion||$127.56 million||215.30|
Globus Medical’s competitors have higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Globus Medical has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Globus Medical’s competitors have a beta of 1.10, meaning that their average stock price is 10% more volatile than the S&P 500.
This table compares Globus Medical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Globus Medical Competitors||-125.29%||-43.73%||-11.32%|
Globus Medical competitors beat Globus Medical on 9 of the 13 factors compared.
About Globus Medical
Globus Medical, Inc. (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies. The Company sells its products through exclusive sales force in the United States, as well as within North, Central & South America, Europe, Asia, Africa and Australia. The sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors.
Receive News & Ratings for Globus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.